Surgical Outcomes From The Phase Iii Checkmate 816 Trial

Surgical outcomes from the Phase III CheckMate 816 trial

CheckMate 816: addressing unanswered questions on surgical outcomes following neoadjuvant chemo-IO

Surgical outcomes from CheckMate 816: NIVO plus chemo vs chemo alone as neoadjuvant treatment fo...

ASCO 2021 Lung Recap: Surgical Outcomes & Checkmate 816: Nivolumab in Early Stage NSCLC

GRACE - Global Resource for Advancing Cancer Education

Dr KRIPA BAJAJ | SURGICAL OUTCOMES FROM THE PHASE 3 CHECKMATE 816 TRIAL Update 19 February 2022

CRSF - Cancer Research and Statistic Foundation

Dr. Patrick Forde Discusses 3-Year CheckMate 816 NSCLC Results at ASCO 2023

Event-free survival results from CheckMate 816

Immunotherapy as combination and neoadjuvant therapies in NSCLC

CheckMate 816 trial: Nivolumab + platinum-doublet chemotherapy vs chemo as neoadjuvant treatment...

CheckMate-816: what does the data tell us?

Checkmate 816: Combining Chemo and Opdivo - ASCO Lung Review 2022

GRACE - Global Resource for Advancing Cancer Education

Perioperative therapies in NSCLC

The CheckMate 816 Trial: The Success of Adjuvant NSCLC Therapies - Lung Cancer OncTalk 2022

GRACE - Global Resource for Advancing Cancer Education

Realizing the Promise of Perioperative Immunotherapy in Resectable NSCLC

PeerView Oncology

Upcoming NSCLC trials in 2022: CheckMate 816 & KEYNOTE-091

Surgical endpoints are needed in lung cancer trials of neoadjuvant therapy

Expert Video Report on featured outcomes from novel NSCLC trials @AACR 2022

European Society for Medical Oncology (ESMO)

Can we improve the surgical outcomes in resectable lung cancer by adding preoperative immunotherapy?

Checkmate 816: Neoadjuvant Nivolumab + Chemotherapy for NSCLC - OncTalk Lung 2023

GRACE - Global Resource for Advancing Cancer Education

Expert report on neoadjuvant immune checkpoint inhibitors for NSCLC

European Society for Medical Oncology (ESMO)